The management team is supported by a strong board of directors composed of senior executives drawn from business, pharma, medical devices and medicine.
Chairman, Founder, Principal Investor and
Chief Science & Strategy Officer of electroCore
JP received his undergraduate degree in aeronautical engineering from the Massachusetts Institute of Technology, and worked at the Air Force National Laboratory, Lincoln Laboratories. He holds both law and mechanical/materials engineering graduate degrees from Duke University.
JP trained as a patent attorney in New York, and is the author of a treatise on international intellectual property law. Along with fellow investor and Board Member, Dr. Errico, Mr. Errico has founded a number of medical device companies, including Fastenetix, K2 Medical, AD-4 Pharma, E2, and SpineCore. Products conceived by these companies have generated more than $8 billion in sales to date.
He served as the CEO of SpineCore from the inception of the company through to its sale to Stryker in July 2004.
JP is a named inventor on more than 125 issued US patents, and is a named inventor on more than 100 pending US applications. Additional patents and patent applications outside the US on which he is a named inventor number greater than 200. In addition to his current role as Chief Science & Strategy Officer, he continues also to make significant inventive contributions in all aspects of the company’s key patent portfolios, along with the clinical and market validations of the company’s products and their indications.
Thomas J. Errico, MD
Founder and Principal Investor
Dr. Errico is a graduate of the New Jersey College of Medicine. After completing a residency in orthopedic surgery, he completed a yearlong fellowship in spinal surgery in Toronto with Dr. John Kostuik.
After his fellowship, Dr. Errico accepted a joint position in the faculties of both Orthopedic Surgery and Neurosurgery at the New York University Medical School. Now a tenured professor in both departments, Dr. Errico is serving as the Chief of Spine Service for both New York University and the Hospital for Joint Diseases.
He is an original member of the North American Spine Society, and served as that society’s President for 2004-5. Along with J.P. Errico, he founded several medical device companies, and according to the MedicineLodge 2001 Spinal Implant Intellectual Property Report, is the most prolific surgeon inventor in the field of spine orthopedics. Dr. Errico has been identified as one of the 10 best orthopedic surgeons in the United States.
Dr. Errico served on the Board of Directors of SpineCore from its inception to sale. It is expected that Dr. Errico will serve as a primary contributor and advisor to electroCore for the development of the company’s products and their indications.
Kathryn K. Theofilos, Esquire
Founder and Principal Investor
Kathryn is president of Theo Development, Inc., a real estate development and management company and vice president of SNJ Properties, Inc., General Partners of Theo Realty Investors.
Kathryn has a B.A. in Economics and Business from the University of California at Los Angeles and graduated from Memphis State University with highest honors from the Cecil C. Humphreys School of Law. Kathryn was admitted into the practice of law in Tennessee and practiced as a Litigation Associate at Heiskell, Donelson, Bearman, Adams, Williams & Kirsch, the largest firm in Tennessee. In 1994, she was admitted into the practice of law in Florida where she became a member of the Florida Bar Association and the Palm Beach County Bar Association, North County Chapter.
In 1998, Theo Development, Inc. was established and acquired as managing partner, Theo Realty Investments, a property investment company with over 150,000 square feet of commercial office/flex, warehouses and 20 acres of prime development land located in Tampa, Florida in 2001.
Peter S. Staats, MD
Peter is an Adjunct Associate Professor in the Department of Anesthesiology and Critical Care Medicine and the Department of Oncology at Johns Hopkins University School of Medicine in Baltimore, Maryland. He was the founder of the Division of Pain Medicine at Johns Hopkins University, where he was the director for ten years.
Peter is internationally known for developing and implementing minimally invasive procedures for chronic pain. Peter received his medical degree from the University of Michigan Medical School in Ann Arbor and completed his residency and fellowship training at the Johns Hopkins University School of Medicine. He is certified by the National Board of Medical Examiners, the American Board of Pain Medicine, and the American Board of Anesthesiology, and is a fellow of the World Institute of Pain and the North American Neuromodulation Society.
Peter has written or co-edited five books, and close to two hundred articles, abstracts, monographs and book chapters on pain medicine in publications that include the Journal of the American Medicine Association, Pain, Anesthesiology, and the Journal of Clinical Oncology. His work has been highlighted on Good Morning America, CBS Evening News and CNN. He has lectured extensively nationally and internationally for over 10 years. In addition to his numerous editorial board appointments including the Clinical Journal of Pain and Pain Medicine, Peter is an active member in many professional societies and is past president of the North American Neuromodulation Society and the Southern Pain Society.
Reese S. Terry, Jr.
Reese brings more than 25 years of relevant medical device industry experience to electroCore. Reese’s distinguished professional career began in 1967 at Cordis Corporation. In 1976, he joined Intermedics, Inc., a medical device and electronics company. Reese served as Vice President of Engineering, Vice President of Corporate Technical Resources and Vice President of Quality. In 1973, he co-developed the first programmable heart pacer.
In 1987 Reese went on to be a co-founder and CEO of Cyberonics, Inc., a company that¹s mission was to develop, manufacture, and market neuromodulation therapies for patients with epilepsy and other inadequately treated neurological disorders. The company received FDA approval for use of its implantable vagal nerve stimulators (VNS) for the treatment of refractory epilepsy in 1997 and in patients with treatment-resistant depression in 2005. Since its founding, more than 100,000 patients worldwide have been implanted with Cyberonics’ VNS. Reese served as the CEO of Cyberonics from 1987 until 1991, and as interim CEO during parts of 1995, 2006 and 2007. He was a member of the Cyberonics’ Board of Directors from 1987 through 2010.
Reese’s medical advancements earned him the Industrial Research, Inc. 100 Award for the Cordis Omnicor Programmable Pacemaker in 1993. He received the 2012 IEEE EMB career achievement award and one of the 2012 Epilepsy Foundation “World Changer” awards.
He received his bachelor’s and master’s degrees in electrical engineering in 1964 and 1966 from the University of Kentucky.
David Rubin, Ph.D.
David is a Managing Director in Merck’s Global Health Innovation fund with a primary focus area on precision medicine. David has invested in molecular diagnostics, point-of-care diagnostics, imaging, and therapeutic device companies that address unmet needs in oncology, infectious disease, neurology, and cardiovascular disease. David holds board seats at OpGen, Daktari Diagnostics, electroCore, and Prophecy; and is a board observer at Asuragen and Genome Dx.David joined Merck in 2007 as Director of Franchise and Portfolio Management. His primary responsibilities were to oversee the operational support of all Merck Research Laboratories (MRL) disease area franchises and provide portfolio management support to MRL Oncology, including the development of franchise strategies, scenario planning, and portfolio valuation. David joined Merck from Cognia Corporation where he was CEO and President, and helped to build it into one of the pioneer bioinformatics products company. Previously, David was at The Wilkerson Group/IBM Global Services in a Strategic Management position supporting pharma, biotech, and diagnostics companies. David holds a Ph.D. from Temple University in Molecular Biology and a BA from SUNY Binghamton in Biology. He was a National Institutes of Health and American Cancer Society Post-Doctoral fellow at Harvard Medical School where he worked on the Ubiquitin Proteasome Pathway. He also received training in post-graduate business at Harvard University.
Trevor is President of TM strategic Advisors LLC, a management consultancy serving the boards, investors and senior management of both emerging and established medical technology companies.
Trevor brings significant experience with over 25 years in the development, commercialization and funding of innovative, growth-oriented medical technologies. He was most recently a General Partner at Frazier Healthcare Ventures, a leading healthcare venture capital and private equity investment firm with $1.8 billion under management. Trevor co-led the medical device team at Frazier and became known as an active and well-regarded investor. Prior to Frazier Healthcare, he was a Senior Consultant at The Wilkerson Group.
Trevor graduated from the Massachusetts Institute of Technology with a Masters of Science in Management (Sloan School) and the University of Southern Queensland, Australia with a Bachelor of Engineering.Trained as a Biomedical Engineer with an electrical focus, he held product development and product marketing roles at Telectronics Pacing Systems and Ventritex, both in the Cardiac Rhythm Management market.
Trevor is also Board Chair of Seattle BioMed, one of the largest independent, non-profit research institutes focused on diseases of the developing world.
Jim Tullis founded Tullis Health Investors (“THI” or “Tullis-Dickerson & Co., Inc.”) in 1986 and has a career of over 40 years in health care investing.
Prior to establishing Tullis Health Investors in 1986, Jim was a Senior Vice President of E.F. Hutton & Co. (1983-1986) and a Principal at Morgan Stanley & Co. (1974-1983), where he led health care investment research and, later, healthcare investment banking. During his tenure at Morgan Stanley, he received recognition fourteen times on the Institutional Investor All-Star list of Wall Street’s top securities analysts and listing as a top home run hitter. He was twice named #1 Drug Analyst and was featured on the Wall Street Week television program. From 1972-1974, Jim was Vice President of Putnam Funds researching health care industry equities.
Under Jim’s direction, THI has managed several venture capital funds investing into the health care industry. Winning portfolio companies of those funds include Adams Respiratory and Sirion (with innovative concepts in pharmaceuticals); Synageva and BioRexis (biotechnology); Atritech, Valeritas and Vidacare (medical devices); PSS World Medical and Impulse Monitoring (medical services); and Intelliclaim and QuadraMed (health care information technology). The Firm’s funds launched since 2000 have achieved top quartile performance in returns to investors, outpacing both comparable health care funds and the S&P averages.
Jim is a graduate of Stanford University and earned an MBA from Harvard Business School. He currently sits on the Boards of the Lord Abbett family of mutual funds, Crane Corporation (NYSE: CR), LivHOME, Inc., SupplyPro, Inc., and electroCore, LLC.
Jim is married to Linda (Stanford, 1970) and lives in North Palm Beach, Florida. Jim and Linda have three married children and eight grandchildren. Jim is a member and former Board Member of Chief Executives Organization and a member of World President’s Organization.